product summary
company name :
Cell Signaling Technology
product type :
antibody
product name :
Phospho-Chk1 (Ser296) Antibody
catalog :
2349
clonality :
polyclonal
host :
rabbit
conjugate :
nonconjugated
antigen modification :
phosphorylated
reactivity :
human
application :
western blot
more info or order :
Cell Signaling Technology product webpage
citations: 16
Published Application/Species/Sample/DilutionReference
  • western blot; human; loading ...; fig 2a
Paculova H, Kramara J, Simečková S, Fedr R, Soucek K, Hylse O, et al. BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors. Tumour Biol. 2017;39:1010428317727479 pubmed publisher
  • western blot; human; loading ...; fig 1d
Nagano T, Nakano M, Nakashima A, Onishi K, Yamao S, Enari M, et al. Identification of cellular senescence-specific genes by comparative transcriptomics. Sci Rep. 2016;6:31758 pubmed publisher
  • western blot; human; fig 1b
Kemp M, Sancar A. ATR Kinase Inhibition Protects Non-cycling Cells from the Lethal Effects of DNA Damage and Transcription Stress. J Biol Chem. 2016;291:9330-42 pubmed publisher
  • western blot; human; 1:1000; fig s4
Ercilla A, Llopis A, Feu S, Aranda S, Ernfors P, Freire R, et al. New origin firing is inhibited by APC/CCdh1 activation in S-phase after severe replication stress. Nucleic Acids Res. 2016;44:4745-62 pubmed publisher
  • western blot; human; fig 2
Abu Odeh M, Hereema N, Aqeilan R. WWOX modulates the ATR-mediated DNA damage checkpoint response. Oncotarget. 2016;7:4344-55 pubmed publisher
  • western blot; human; fig 1
Sakurikar N, Thompson R, Montano R, Eastman A. A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase. Oncotarget. 2016;7:1380-94 pubmed publisher
  • western blot; human; 1:1000; fig 8
Domínguez D, Feijoo P, Bernal A, Ercilla A, Agell N, Genescà A, et al. Centrosome aberrations in human mammary epithelial cells driven by cooperative interactions between p16INK4a deficiency and telomere-dependent genotoxic stress. Oncotarget. 2015;6:28238-56 pubmed publisher
  • western blot; human; fig s4
Zuazua Villar P, Ganesh A, Phear G, Gagou M, Meuth M. Extensive RPA2 hyperphosphorylation promotes apoptosis in response to DNA replication stress in CHK1 inhibited cells. Nucleic Acids Res. 2015;43:9776-87 pubmed publisher
  • western blot; human; fig 6
King C, Diaz H, McNeely S, Barnard D, Dempsey J, Blosser W, et al. LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms. Mol Cancer Ther. 2015;14:2004-13 pubmed publisher
  • western blot; human; 1:1000; fig 4
Mackay D, Ullman K. ATR and a Chk1-Aurora B pathway coordinate postmitotic genome surveillance with cytokinetic abscission. Mol Biol Cell. 2015;26:2217-26 pubmed publisher
  • western blot; human
Kemp M, Lindsey Boltz L, Sancar A. UV Light Potentiates STING (Stimulator of Interferon Genes)-dependent Innate Immune Signaling through Deregulation of ULK1 (Unc51-like Kinase 1). J Biol Chem. 2015;290:12184-94 pubmed publisher
  • western blot; human; fig 3
Wang W, Catto J, Meuth M. Differential response of normal and malignant urothelial cells to CHK1 and ATM inhibitors. Oncogene. 2015;34:2887-96 pubmed publisher
  • western blot; human; 1:1000; fig 2a
Martino Echarri E, Henderson B, Brocardo M. Targeting the DNA replication checkpoint by pharmacologic inhibition of Chk1 kinase: a strategy to sensitize APC mutant colon cancer cells to 5-fluorouracil chemotherapy. Oncotarget. 2014;5:9889-900 pubmed
Richardson E, Stockwell S, Li H, Aherne W, Cuomo M, Mittnacht S. Mechanism-based screen establishes signalling framework for DNA damage-associated G1 checkpoint response. PLoS ONE. 2012;7:e31627 pubmed publisher
Nam E, Zhao R, Glick G, Bansbach C, Friedman D, Cortez D. Thr-1989 phosphorylation is a marker of active ataxia telangiectasia-mutated and Rad3-related (ATR) kinase. J Biol Chem. 2011;286:28707-14 pubmed publisher
Robinson K, Asawachaicharn N, Galloway D, Grandori C. c-Myc accelerates S-phase and requires WRN to avoid replication stress. PLoS ONE. 2009;4:e5951 pubmed publisher
product information
SKU :
2349S
Product-Name :
Phospho-Chk1 (Ser296) Antibody
Size :
100 ul
Price-(USD) :
274 USD
Species-x-Reactivity :
H, Mk
Applications :
Western blot
Product-Category :
Cell Cycle / Checkpoint Control
Shipping-Temp :
AMBIENT
Storage-Temp :
-20°C
Product-Type :
Polyclonal Antibody
MW :
56
Host :
Rabbit
Target :
Chk1 (Ser296) phosphate
Primary-Protein :
Chk1
Alt-Names :
CHEK1,CHK1,CHK1 checkpoint homolog (S. pombe),Checkpoint, S. pombe, homolog of, 1,Serine/threonine-protein kinase Chk1
more info or order :
Cell Signaling Technology product webpage
company information
Cell Signaling Technology
3 Trask Lane
Danvers, MA 01923
info@cellsignal.com
www.cellsignal.com
8776162355
headquarters: USA
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine.